Myelofibrosis: A Review

This article provides the most current information on therapeutic targeting in myeloprolifarative neoplasms with a focus on MPN disease biology. Anne Mullally: We need to expand our risk stratification of MPN beyond just thrombotic risk. Francesco Passamonti and Barbara Moa discuss myelofibrosis. Anagrine and clarhearism analyze essential from polycytemia, challenges in clinical practice and future prospects.